References
- Guarascio AJ, Ray SM, Finch CK, Self TH. The clinical and economic burden of chronic obstructive pulmonary disease in the USA. Clinicoecon Outcomes Res 2013; 5:235–245.
- Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361(9356):449–456.
- Calverley PM, Walker P. Chronic obstructive pulmonary disease. Lancet 2003; 362(9389):1053–1061.
- Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356(8):775–789.
- Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013; 187(4):347–365.
- Healthcare Cost and Utilization Project (HCUP) databases. Agency for HealthcareResearch and Quality. http://www.hcup-us.ahrq.gov/databases.jsp. 2013.
- Patil SP, Krishnan JA, Lechtzin N, Diette GB. In-hospital mortality following acute exacerbations of chronic obstructive pulmonary disease. Arch Intern Med 2003; 163(10):1180–1186.
- O'Reilly JF, Williams AE, Holt K, Rice L. Defining COPD exacerbations: impact on estimation of incidence and burden in primary care. Prim Care Respir J 2006; 15(6):346–353.
- Moore KD, Eyestone K, Coddington DC. The healthcare cost curve can be bent. Healthc Financ Manage 2013; 67(3):78–84.
- Hilleman DE, Dewan N, Malesker M, Friedman M. Pharmacoeconomic evaluation of COPD. Chest 2000; 118(5):1278–1285.
- Blecker S, Paul M, Taksler G, Ogedegbe G, Katz S. Heart failure-associated hospitalizations in the United States. J Am Coll Cardiol 2013; 61(12):1259–1267.
- Holland A. Telehealth reduces hospital admission rates in patients with COPD. J Physiother 2013; 59(2):129.